Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-Viral Central Memory CD8 Veto Cells in Haploidentical Hematopoietic Stem Cell Transplantation
NCT03622788Phase 2Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Aug 2019
- Primary completion
- Dec 2027
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Cytokine-treated Veto Cells in hematologic malignancy, aplastic anemia and bone marrow failure, sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Optimal dose of donor-derived cytokine-treated veto cells at 42 days and Efficacy of veto cells at 42 days. Started Aug 2019; status: active, not recruiting.
02
Drugs
Cytokine-treated Veto Cells
03
Conditions
hematologic malignancyaplastic anemiabone marrow failure
Beyond the preview
Go deeper on NCT03622788.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03622788.